Rare NRG1 Fusion Market Outlook 2032 | Key Assessment into the Epidemiology Trends, Evolving Market Dynamics, Ongoing Therapeutic Developments, Emerging Therapies, and Key Players by DelveInsight

As per DelveInsight, the Rare NRG1 Fusion Market is set to evolve significantly in the coming years owing to the improvement in the research and development activities so that the market will comprise efficient treatment options. The launch of emerging therapies is expected in the near future. Moreover, the rise in the number of incident cases will also stimulate market growth.

The pipeline of drugs for Rare NRG1 Fusion is quite weak as it possesses very few potential key players, such as Elevation Oncology, Merus and Rain Therapeutics. Additionally, Hummingbird Bioscience also has a lead candidate in the early stages of development. Due to the relative novelty of the mutation and lack of extensive research and development, the pipeline of rare NRG1 fusions is still evolving, and most of the drugs are still in the very early phase of development.

DelveInsight's "Rare NRG1 Fusion Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Rare NRG1 Fusion Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Rare NRG1 Fusion market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Rare NRG1 Fusion: An Overview
The neuregulin-1 (NRG1) gene encodes for neuregulin 1, a growth factor belonging to the complex family of proteins also called heregulins. These proteins are structurally related to the stimulation of ERBB receptors tyrosine kinase activity, and EGF signals. Specifically, the NRG1-receptor binding induces the phosphorylation of the intrinsic kinase domains of ERBB3 and stimulates its dimerization with ERBB2 receptor and the activation of the downstream PI3K-AKT and MAPK pathways.

NRG1 fusions are a rare but powerful oncogene driver that makes cancer particularly aggressive and deadly when it is present. Therefore, they have emerged as a potential therapeutic target across multiple tumor types.

Rare NRG1 Fusion Market Key Facts
- In 2021, the total incident case of Rare NRG1 Fusion were 5,700+ cases in the 7MM, which are expected to grow during the forecast period (2019-32).
- The Rare NRG1 Fusion Therapeutic Market in the seven major markets is expected to increase during the study period (2019-2032) with a CAGR of 25.9%.
- According to the estimates, the highest market size of NRG1 Fusion is found in the United States, followed by Japan.
- In the year 2021, the total incident cases of Rare NRG1 Fusion were 5,700+ in the 7MM, which are expected to grow by 2032.
- In the United States, the total number of incident cases of NRG1 Fusion was 2,100+ in the year 2021, which is expected to grow during the study period, i.e., 2019-2032. In the US, NSCLC and Breast cancer have the highest number of NRG1 fusion cases.
- In 2021, the total incident cases of NRG1 Fusion in EU-5 were highest in Germany, which is expected to grow during the study period, i.e., 2019-2032.
- Among emerging therapies, Zenocutuzumab from Merus is expected to garner the highest patient share owing to novel MOA, visibility around the efficacy data from the ongoing trials, and also the early mover advantage.

Rare NRG1 Fusion Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Rare NRG1 Fusion market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Rare NRG1 Fusion market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Rare NRG1 Fusion Market will Grow by 2032:
https://www.delveinsight.com/report-store/rare-nrg1-fusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Rare NRG1 Fusion Epidemiology
The epidemiology section covers detailed insights into the historical and current Rare NRG1 Fusion patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Rare NRG1 Fusion Epidemiology, Segmented by -
- Incident cases of specific cancer types (lung, pancreatic, breast, and others) in the 7MM (2019-32)
- Diagnosed and Treatable Cases of Rare NRG1 Fusion in the respective cancer types in the 7MM (2019-32)
- Incident cases of Rare NRG1 Fusion in the respective cancer types in the 7MM (2019-32)

Rare NRG1 Fusion Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Rare NRG1 Fusion market or expected to get launched in the market during the study period. The analysis covers Rare NRG1 Fusion market uptake by drugs, patient uptake by therapies, and sales of each drug.

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. The report also covers the Rare NRG1 Fusion Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Rare NRG1 Fusion Therapeutics Assessment
NRG1 gene fusions result in the activation of ErbB2-/ErbB3-mediated signaling pathways and may function as oncogenic drivers. NRG1 fusions have emerged as a potential therapeutic target across multiple tumor types, including NSCLC.

For NRG1 fusions, there are currently no approved targeted therapies. Standard therapy for advanced tumors harboring NRG1 fusions remains chemotherapy and immunotherapy or novel anti-PD-1 or anti-PD-L1 agents. The problem with utilizing these therapies is that response tends to be suboptimal for patients with NRG1 fusions. Several clinical reports have demonstrated that NRG1 fusions are a viable, actionable target in tumors, with responses seen on inhibition of ERBB family members.

The Leading Companies in the Rare NRG1 Fusion Market Include:
- Elevation Oncology
- Hummingbird Bioscience
- Boehringer Ingelheim
- Merus
- AVEO Oncology
- CANbridge Pharmaceuticals
- Salubris Biotherapeutics
And many others

Rare NRG1 Fusion Drugs Covered in the Report Include:
- MM-121/Seribantumab (Elevation Oncology)
- HMBD-001 (Hummingbird Bioscience)
- Zenocutuzumab/MCLA-128 (Merus)
- Tarloxotinib (Rain Therapeutics)
- AV-203/CAN017 (CANbridge Pharmaceuticals/AVEO Oncology)
And many more

Learn More About the Emerging Therapies & Key Companies in the Rare NRG1 Fusion Therapeutics Market:
https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Rare NRG1 Fusion Competitive Intelligence Analysis
4. Rare NRG1 Fusion Market Overview at a Glance
5. Rare NRG1 Fusion Background and Overview
6. Rare NRG1 Fusion Patient Journey
7. Rare NRG1 Fusion Epidemiology and Patient Population
8. Rare NRG1 Fusion Treatment Algorithm, Current Treatment, and Medical Practices
9. Rare NRG1 Fusion Unmet Needs
10. Key Endpoints of Rare NRG1 Fusion Treatment
11. Rare NRG1 Fusion Marketed Products
12. Rare NRG1 Fusion Emerging Therapies
13. Rare NRG1 Fusion Seven Major Market Analysis
14. Attribute Analysis
15. Rare NRG1 Fusion Market Outlook (7 major markets)
16. Rare NRG1 Fusion Access and Reimbursement Overview
17. KOL Views on the Rare NRG1 Fusion Market.
18. Rare NRG1 Fusion Market Drivers
19. Rare NRG1 Fusion Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Download the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.